Jump to main content
Jump to site search


Enhance cellular uptake by non-endocytic pathway for tumor therapy

Abstract

Endosome/lysosome, as the potential risk of therapeutic inactivation resulted from physical obstruction and a number of acid hydrolases, is a bottleneck in effective intracellular delivery which needs to be overcome. One promising strategy to avoid this barrier is to deliver therapeutic agents directly to cytoplasm. In this work, CLIP6 peptide (KVRVRVRVDPPTRVRERVK-NH2) which can facilitate non-endosomal cell entry and anticancer drug doxorubicin (DOX) were covalently grafted to N-(2-hydroxypropyl) methacrylamide (HPMA) backbone (P-DOX-CLIP6). As a result, CLIP6 peptide modification increased the cellular uptake of DOX-loaded HPMA copolymers. Importantly, it effectively reduced lysosomal accumulation, leading to stronger proliferation inhibition and superior growth inhibition effect on three-dimensional tumor spheroids, compared to unmodified HPMA copolymer conjugates. Furthermore, P-CLIP6-DOX induced the highest therapeutic efficacy in HeLa tumor-bearing nude mouse. Meanwhile, no significant systemic toxicity was observed during treatment. In conclusion, this study provided a promising strategy to efficiently deliver drug candidates which were limited by endo/lysosomal trapping.

Back to tab navigation

Supplementary files

Publication details

The article was received on 29 Jun 2018, accepted on 08 Oct 2018 and first published on 08 Oct 2018


Article type: Paper
DOI: 10.1039/C8TB01698D
Citation: J. Mater. Chem. B, 2018, Accepted Manuscript
  •   Request permissions

    Enhance cellular uptake by non-endocytic pathway for tumor therapy

    Y. Liu, Q. Li, X. Xiong, Y. Huang and Z. Zhou, J. Mater. Chem. B, 2018, Accepted Manuscript , DOI: 10.1039/C8TB01698D

Search articles by author

Spotlight

Advertisements